Stock Research for IBB

Featured Broker: Ally Invest

Get the due diligence for another stock.


IBB Stock Chart & Research Data

The IBB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IBB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


IBB Due diligence Resources & Stock Charts

The IBB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IBB Detailed Price Forecast - CNN Money CNN View IBB Detailed Summary - Google Finance
Yahoo View IBB Detailed Summary - Yahoo! Finance Zacks View IBB Stock Research & Analysis -

Stock Analysis

TradeIdeas View IBB Trends & Analysis - Trade-Ideas Barrons View IBB Major Holders - Barrons
NASDAQ View IBB Call Transcripts - NASDAQ Seeking View IBB Breaking News & Analysis - Seeking Alpha
Spotlight View IBB Annual Report - OTC Report View IBB OTC Short Report -
TradeKing View IBB Fundamentals - TradeKing Charts View IBB SEC Filings - Bar Chart
WSJ View Historical Prices for IBB - The WSJ Morningstar View Performance/Total Return for IBB - Morningstar
MarketWatch View the Analyst Estimates for IBB - MarketWatch CNBC View the Earnings History for IBB - CNBC
StockMarketWatch View the IBB Earnings - StockMarketWatch MacroAxis View IBB Buy or Sell Recommendations - MacroAxis
Bullish View the IBB Bullish Patterns - American Bulls Short Pains View IBB Short Pain Metrics -

Social Media Mentions

StockTwits View IBB Stock Mentions - StockTwits PennyStocks View IBB Stock Mentions - PennyStockTweets
Twitter View IBB Stock Mentions - Twitter Invest Hub View IBB Investment Forum News - Investor Hub
Yahoo View IBB Stock Mentions - Yahoo! Message Board Seeking Alpha View IBB Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for IBB - Insider Cow View Insider Transactions for IBB - Insider Cow
CNBC View IBB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IBB - OTC Markets
Yahoo View Insider Transactions for IBB - Yahoo! Finance NASDAQ View Institutional Holdings for IBB - NASDAQ

Stock Charts

FinViz View IBB Stock Insight & Charts - StockCharts View IBB Investment Charts -
BarChart View IBB Stock Overview & Charts - BarChart Trading View View IBB User Generated Charts - Trading View

Latest Financial News for IBB

Biotech Stocks Could Lead Summer Rally
Posted on Friday May 25, 2018

Biotech stocks turned higher on May 11 after President Trump outlined a series of steps the administration might take to control skyrocketing drug prices. The lack of details triggered a relief rally underpinned by skepticism that the initiatives will pass Congress and their deep reliance on industry contributions.

How Ionis’s Spinraza Did in Q1
Posted on Friday May 25, 2018

Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

Analyzing ABMD, BR, and TFX Stocks
Posted on Monday May 21, 2018

Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively. The company’s pre-tax margin grew from 10.7% in 2013 to 20.5% in 2017. ABMD beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 680% between 2013 and 2017.

Amgen Stock Rises over 2% on Drug Approvals
Posted on Friday May 18, 2018

On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

Enter a stock symbol to view the stock details.